Emerging data suggest Retatrutide , a website dual agonist targeting both incretin and another hormone, may provide a notable step forward for obesity management . Early patient tests have demonstrated substantial reductions in visceral tissue, possibly outperforming current body composition treatments. However , further study is needed to fully un